Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “subcutaneous”

20 pharma patents match "subcutaneous" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 20
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 20 pharmaceutical patents matching "subcutaneous" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

20 results for “subcutaneous” · 30,257 patents in full index Clear search

  1. US 12371506

    Subcutaneous administration of anti-CD38 antibodies

    Takeda Pharmaceutical Company Limited · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted

  2. US 12076397

    Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted

  3. US 11944618

    Subcutaneous delivery of polymer conjugates of therapeutic agents

    Serina Therapeutics, Inc. · Granted Apr 2, 2024 · Expires Mar 28, 2044

    granted

  4. US 11779635

    Subcutaneous administration of ADAMTS13

    Takeda Pharmaceutical Company Limited · Granted Oct 10, 2023 · Expires Oct 5, 2043

    granted

  5. US 11491212

    Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B

    Catalyst Biosciences, Inc. · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted

  6. US 11298350

    Subcutaneous delivery of polymer conjugates of therapeutics agents

    Serina Therapeutics, Inc. · Granted Apr 12, 2022 · Expires Apr 7, 2042

    granted

  7. US 11266724

    Modified factor VII polypeptides for subcutaneous administration and on-demand treatment

    Catalyst Biosciences, Inc. · Granted Mar 8, 2022 · Expires Mar 3, 2042

    granted

  8. US 11242380

    Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use

    Takeda Pharmaceutical Company Limited · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted

  9. US 11224595

    Subcutaneous delivery of poly(oxazoline) polymer conjugates

    Serina Therapeutics, Inc. · Granted Jan 18, 2022 · Expires Jan 13, 2042

    granted

  10. US 11213524

    Pharmaceutical compositions for subcutaneous administration of levosimendan

    TENAX THERAPEUTICS, INC. · Granted Jan 4, 2022 · Expires Dec 30, 2041

    granted

  11. US 11185575

    Subcutaneous administration of ADAMTS13

    Takeda Pharmaceutical Company Limited · Granted Nov 30, 2021 · Expires Nov 25, 2041

    granted

  12. US 11129940

    Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes

    XERIS PHARMACEUTICALS, INC. · Granted Sep 28, 2021 · Expires Sep 23, 2041

    granted

  13. US 10844102

    Peptides, compositions, and methods for stimulating subcutaneous adipogenesis

    The Regents of the University of California · Granted Nov 24, 2020 · Expires Nov 19, 2040

    granted

  14. US 10766927

    Peptides that stimulate subcutaneous adipogenesis

    The Regents of the University of California · Granted Sep 8, 2020 · Expires Sep 3, 2040

    granted

  15. US 2020155578

    Pharmaceutical Formulations for Subcutaneous Administration

    ABBVIE INC [US] · Granted May 21, 2020 · Expires May 16, 2040

    granted

  16. US 10494402

    Peptides that stimulate subcutaneous adipogenesis

    The Regents of the University of California · Granted Dec 3, 2019 · Expires Nov 28, 2039

    granted

  17. US 10314837

    Subcutaneous delivery of poly(oxazoline) polymer conjugates

    Serina Therapeutics, Inc. · Granted Jun 11, 2019 · Expires Jun 6, 2039

    granted

  18. US 8952067

    Subcutaneous fat reduction

    Atheronova Operations, Inc. · Granted Feb 10, 2015 · Expires Feb 5, 2035

    granted

  19. US 8597633

    Subcutaneous delivery of poly(oxazoline) conjugates

    Serina Therapeutics, Inc. · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  20. US 8383093

    Subcutaneous delivery of poly(oxazoline) conjugates

    Serina Therapeutics, Inc. · Granted Feb 26, 2013 · Expires Feb 21, 2033

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.